本帖最后由 老马 于 2012-1-13 21:20 编辑 - T" P% n3 _. k* G& d9 B
, O- b" D7 T. n& v2 u4 X3 _
爱必妥和阿瓦斯丁的比较1 B* l, \$ T9 ?2 c M
Z& R& w9 |" m( ]( B, s# v: G2 O ^http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
; W0 e) {+ Q5 R* x# G
/ D% d$ E+ ~2 R8 ^* Z3 q
$ Z, o- i* D4 Q2 S
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
; f; K8 B4 |1 l==================================================
: Q# K/ g* z8 ^, UOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)0 x6 d/ N0 E5 J2 ~* {& E( d, ]
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.+ ]4 I; F# y4 P$ E7 q! \
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
$ E, A% ^2 o9 b
|
显身卡
. w7 v8 f3 u, j, h: S1 c
